CD147 overexpression allows an accurate discrimination of bladder cancer patients' prognosis

European Journal of Surgical Oncology

Volumn 37, Issue 9, 2011, Pages 811-817

  Afonso, J ^a,b,c   Longatto Filho, A ^a,b,d   Baltazar, F ^a,b   Sousa, N ^e   Costa, F E ^a,b   Morais, A ^e   Amaro, T ^e   Lopes, C ^e,f   Santos, L L ^e,g  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c Alto Ave Superior Institute of Health ISAVE ^*  (Portugal)

^d SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^e PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^f UNIVERSITY OF PORTO   (Portugal)

^g UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Bladder cancer; CD147; Heparanase; Lymphovascular invasion; Scoring system

Indexed keywords

CD147 ANTIGEN; CD31 ANTIGEN; HEPARANASE; MONOCLONAL ANTIBODY D2-40;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER STAGING; CORRELATION ANALYSIS; CYSTECTOMY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; UROTHELIAL BLADDER CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD147; ANTIGENS, CD31; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; FEMALE; GLUCURONIDASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC VESSELS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 80051670916     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2011.06.006     Document Type: Article

References (30)

1. M.J. Droller Bladder cancer: state-of-the-art care CA Cancer J Clin 48 1998 269 284 (Pubitemid 28428769)
2. D.S. Kaufman, W.U. Shipley, and A.S. Feldman Bladder cancer Lancet 374 2009 239 249
3. C. Wiesner, J. Pfitzenmaier, A. Faldum, R. Gillitzer, S.W. Melchior, and J.W. Thüroff Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral ressections and tumour upstaging at radical cystectomy BJU Int 95 2005 301 305 (Pubitemid 40283112)
4. C.N. Sternberg, S.M. Donat, and J. Bellmunt Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer Urology 69 1 2007 62 79 (Pubitemid 46186484)
5. H. von der Maase, S.W. Hansen, and J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 2000 1817 3068 3077
6. J. Walz, S.F. Shariat, and N. Suardi Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case control study BJU Int 101 11 2008 1356 1361 (Pubitemid 351623984)
7. P.E. Clark Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer Expert Rev Anticancer Ther 9 6 2009 821 830
8. H.B. Grossman, R.B. Natale, and C.M. Tangen Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 34 2003 859 866 (Pubitemid 37025405)
9. R. Takata, T. Katagiri, and M. Kanehira Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling Clin Cancer Res 11 7 2005 2625 2636 (Pubitemid 40569463)
10. P. Kirk, W.C. Wilson, C. Heddle, M.H. Brown, A.N. Barclay, and A.P. Halestrap CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitated their cell surface expression EMBO 19 2000 3896 3904 (Pubitemid 30608530)
11. E.E. Gabison, T. Hoang-Xuan, A. Mauviel, and S. Menashi EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair Biochimie 87 2005 361 368 (Pubitemid 40387615)
12. A.B. Als, L. Dyrskjøt, and H. von derMaase Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer Clin Cancer Res 13 15 2007 4407 4414 (Pubitemid 47219707)
13. Z. Han, H. He, and X. Bi Expression and clinical significance of CD147 in genitourinary carcinomas J Surg Res 160 2 2010 260 267
14. Y.-J. Xue, Q. Lu, and Z.-X. Sun CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer Med Oncol 2010 10.1007/s12032-010-9582-4
15. I. Vlodavsky, and Y. Friedmann Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis J Clin Invest 108 2001 341 347 (Pubitemid 32730777)
16. K. Gohji, H. Hirano, and M. Okamoto Expression of three extracellular matriz degradative enzymes in bladder cancer Int J Cancer 95 2001 295 301 (Pubitemid 32847039)
17. V. Cohen-Kaplan, I. Naroditsky, A. Zetser, N. Ilan, I. Vlodavsky, and I. Doweck Heparanase induces VEGF-C and facilitates tumour lymphangiogenesis Int J Cancer 123 2008 2566 2573
18. R.H. Adams, and K. Alitalo Molecular regulation of angiogenesis and lymphangiogenesis Nat Rev 8 2007 464 478 (Pubitemid 46823443)
19. E.I. Harris, D.N. Lewin, and H.L. Wang Lymphovascular invasion in colorectal cancer: an interobserver variability study Am J Surg Pathol 32 12 2008 1816 1821
20. C. Bolenz, E. Herrmann, and P.J. Bastian Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial BJU Int 106 4 2010 493 499
21. J. Afonso, L.L. Santos, T. Amaro, F. Lobo, and A. Longatto-Filho The aggressiveness of urothelial carcinoma depends to a large extent on lymphovascular invasion - the prognostic contribution of related molecular markers Histopathology 55 2009 514 524
22. M.B. Amin, J.R. Srigley, and D.J. Grignon Urinary bladder cancer protocols and checklists 2005 College of American Pathologists Northfield, IL
23. F.L. Greene, D.L. Page, I.D. Fleming, A. Fritz, C.M. Balch, D.G. Haller, and M. Morrow AJCC cancer staging manual 6th ed 2002 Springer Verlag New York
24. J.N. Eble, G. Sauter, J.I. Epstein, and I.A. Sesterhenn World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organ 2004 IARC Press Lyon
25. J.M. Yang, Z. Xu, H. Wu, H. Zhu, X. Wu, and W.N. Hait Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells Mol Cancer Res 1 2003 420 427 (Pubitemid 36459252)
26. U.A. German P-glycoprotein - a mediator of multidrug resistance in tumour cells Eur J Cancer 32A 1996 927 944
27. H. Chen, L. Wang, J. Beretov, J. Hao, W. Xiao, and Y. Li Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multidrug resistance proteins is associated with epithelial ovarian cancer progression Clin Exp Metastasis 27 8 2010 557 569
28. J. Hao, H. Chen, and M.C. Madigan Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression Br J Cancer 103 7 2010 1008 1018
29. S. Misra, S. Ghatak, A. Zoltan-Jones, and B.P. Toole Regulation of multidrug resistance in cancer cells by hyaluronan J Biol Chem 278 2003 25285 25288 (Pubitemid 36835275)
30. E.A. Marieb, A. Zoltan-Jones, and R. Li Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production Cancer Res 64 2004 1229 1232 (Pubitemid 38235586)